- Home
- DAVE vs TVTX Comparison
DAVE vs TVTX Comparison
Compare DAVE & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVE | TVTX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DAVE | TVTX |
|---|---|---|
| Price | $184.05 | $27.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $282.17 | $37.21 |
| AVG Volume (30 Days) | 475.4K | ★ 3.2M |
| Earning Date | 03-02-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 224.46 | N/A |
| EPS | ★ 10.12 | N/A |
| Revenue | ★ $491,301,000.00 | $435,826,000.00 |
| Revenue This Year | $56.88 | $120.02 |
| Revenue Next Year | $18.07 | $37.00 |
| P/E Ratio | $19.17 | ★ N/A |
| Revenue Growth | 53.84 | ★ 114.22 |
| 52 Week Low | $65.46 | $12.91 |
| 52 Week High | $286.45 | $42.13 |
Technical Indicators
Market Signals| Indicator | DAVE | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 28.14 |
| Support Level | $179.00 | $22.59 |
| Resistance Level | $201.07 | $29.31 |
| Average True Range (ATR) | 14.79 | 2.44 |
| MACD | -5.13 | -1.18 |
| Stochastic Oscillator | 9.24 | 28.11 |
Price Performance
Historical ComparisonAbout DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.